bluebird bio to Present at Chardan Gene Therapy Conference
October 06 2017 - 4:16PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company
committed to developing potentially transformative gene therapies
for serious genetic diseases and T cell-based immunotherapies for
cancer, today announced that members of the management team will
present at the Chardan Gene Therapy Conference on Tuesday, October
10, 3:00 pm ET at the Westin Grand Central, New York City.
To access the live webcast of bluebird bio’s presentation,
please visit the “Calendar of Events” page within the Investors and
Media section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcast will be
available on the bluebird bio website for 90 days following the
conference.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the Company’s product candidates and
research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks that the
preliminary results from our clinical trials will not continue or
be repeated in our ongoing clinical trials, the risk of cessation
or delay of any of the ongoing or planned clinical studies and/or
our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, risks that the
current or planned clinical trials of the LentiGlobin drug product
will be insufficient to support regulatory submissions or marketing
approval in the United States and European Union, the risk
that our collaborations, including the collaboration
with Celgene, will not continue or will not be successful, and
the risk that any one or more of our product candidates will not be
successfully developed, approved or commercialized. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our annual report on Form 10-K and our
most recent quarterly report on Form 10-Q, as well as discussions
of potential risks, uncertainties, and other important factors in
our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and bluebird bio undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171006005753/en/
Investors & Mediabluebird bioElizabeth Pingpank,
617-914-8736epingpank@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024